<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report the first prospective study evaluating the effects of <z:chebi fb="0" ids="49005">deferasirox</z:chebi> on liver iron concentration (LIC), labile plasma iron (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LPI</z:e>) and pharmacokinetics (PK) along with serum ferritin values in patients with IPSS Low- and Intermediate-1 risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and evidence of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-four heavily transfused <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were enrolled in a planned 52 weeks of therapy </plain></SENT>
<SENT sid="2" pm="."><plain>PK studies showed dose-proportional total drug exposure </plain></SENT>
<SENT sid="3" pm="."><plain>Data demonstrated that <z:chebi fb="0" ids="49005">deferasirox</z:chebi> was well tolerated and effectively reduced LIC, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LPI</z:e> and serum ferritin in the iron-overloaded patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who completed 24 and 52 weeks of therapy despite ongoing receipt of red blood cell transfusions </plain></SENT>
</text></document>